RT Journal Article
T1 Adjuvant treatment of melanoma.
A1 Moreno Nogueira, J A
A1 Valero Arbizu, M
A1 Pérez Temprano, R
K1 Proliferación de la célula
K1 Interferón-alfa
K1 Ganglios linfáticos
K1 Melanoma
K1 Recurrencia local de neoplasia
K1 Fosfatidilinositol 3-quinasas
AB Melanomas represent 4% of all malignant tumors of the skin, yet account for 80% of deaths from skin cancer.While in the early stages patients can be successfully treated with surgical resection, metastatic melanoma prognosis is dismal. Several oncogenes have been identified in melanoma as BRAF, NRAS, c-Kit, and GNA11 GNAQ, each capable of activating MAPK pathway that increases cell proliferation and promotes angiogenesis, although NRAS and c-Kit also activate PI3 kinase pathway, including being more commonly BRAF activated oncogene. The treatment of choice for localised primary cutaneous melanoma is surgery plus lymphadenectomy if regional lymph nodes are involved. The justification for treatment in addition to surgery is based on the poor prognosis for high risk melanomas with a relapse index of 50-80%. Patients included in the high risk group should be assessed for adjuvant treatment with high doses of Interferon- α 2b, as it is the only treatment shown to significantly improve disease free and possibly global survival. In the future we will have to analyze all these therapeutic possibilities on specific targets, probably associated with chemotherapy and/or interferon in the adjuvant treatment, if we want to change the natural history of melanomas.
PB Hindawi Publishing Corporation
YR 2013
FD 2013
LK http://hdl.handle.net/10668/2174
UL http://hdl.handle.net/10668/2174
LA en
NO Moreno Nogueira JA, Valero Arbizu M, Pérez Temprano R. Adjuvant treatment of melanoma. ISRN Dermatol; 2013:545631
NO Journal Article;
DS RISalud
RD Apr 7, 2025